Leiomyosarcoma laboratory tests

	Leiomyosarcoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Leiomyosarcoma from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Leiomyosarcoma laboratory tests On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Leiomyosarcoma laboratory tests All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Leiomyosarcoma laboratory tests
CDC on Leiomyosarcoma laboratory tests
Leiomyosarcoma laboratory tests in the news
Blogs on Leiomyosarcoma laboratory tests
Directions to Hospitals Treating Leiomyosarcoma
Risk calculators and risk factors for Leiomyosarcoma laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]

Overview:[edit | edit source]

There are no specific laboratory findings associated with leiomyosarcoma, patients may have low hemoglobin and red blood cells on their complete blood count, immunohistochemistry markers can be positive but non-diagnostics.

Lab test:[edit | edit source]

There are no specific laboratory findings associated with leiomyosarcoma.
Elevated levels of CA-125 and LDH( isozymes) in women with uterine sarcoma, the usefulness of these markers are still being investigated.
There are immunohistochemistry markers associated with sarcoma but it can be positive in any other soft tissue tumors, some of these markers are include:^[1]^[2]^[3]
- Actin and desmin positive.
- Diffusely positive with calponin, h-caldesmon.
- Negative with S100, c-kit and CD34

References[edit | edit source]

↑ R, Stramare; G, Orsatti (2016). "Imaging Features, Differential Diagnosis and Management of Leiomyosarcomas: Case Series and Review of the Literature". Journal of Cancer Science & Therapy. 08 (04). doi:10.4172/1948-5956.1000397. ISSN 1948-5956.
↑ Goto A, Takeuchi S, Sugimura K, Maruo T (2002) Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus. Int J Gynecol Cancer 12 (4):354-61. PMID: 12144683
↑ Hoskins PJ, Le N (2008) Preoperative tumor markers at diagnosis in women with malignant mixed müllerian tumors/carcinosarcoma of the uterus. Int J Gynecol Cancer 18 (6):1200-1. DOI:10.1111/j.1525-1438.2007.01187.x PMID: 18217961

Template:WikiDoc Sources

[RG2016-1] R, Stramare; G, Orsatti (2016). "Imaging Features, Differential Diagnosis and Management of Leiomyosarcomas: Case Series and Review of the Literature". Journal of Cancer Science & Therapy. 08 (04). doi:10.4172/1948-5956.1000397. ISSN 1948-5956.

[pmid12144683-2] Goto A, Takeuchi S, Sugimura K, Maruo T (2002) Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus. Int J Gynecol Cancer 12 (4):354-61. PMID: 12144683

[pmid18217961-3] Hoskins PJ, Le N (2008) Preoperative tumor markers at diagnosis in women with malignant mixed müllerian tumors/carcinosarcoma of the uterus. Int J Gynecol Cancer 18 (6):1200-1. DOI:10.1111/j.1525-1438.2007.01187.x PMID: 18217961

[1]

[2]

[3]